Nuvectis Pharma(NASDAQ) NVCT

Nuvectis Pharma creates special medicines to treat cancer. It also makes drugs for people with rare blood diseases. These treatments help patients who have few other medical options.

Fighting Cancer with Precision

• NXP100 (Factor B Inhibitor): Oral drug for rare blood and kidney diseases; approved in China for patients with paroxysmal nocturnal hemoglobinuria, a rare blood disorder.
• NXP200 (BRAF Inhibitor): Brain-penetrant treatment designed to overcome drug resistance in multiple solid tumor types and primary brain cancer.
• NXP900 (SRC/YES1 Inhibitor): Small molecule drug candidate that blocks specific proteins to treat various forms of cancer.
• NXP800 (HSF1 Pathway Inhibitor): Experimental compound designed to block certain signals inside cells to treat various forms of cancer.

New Partnerships and Funding

• Licensed world-wide rights, excluding China, to NXP100 and NXP200 from Haisco Pharmaceutical Group in June 2026.
• Commenced Phase 1b clinical trials for NXP900 as a single agent in August 2025 and in combination with other therapies in December 2025.
• Raised approximately $106.3 million in net proceeds through a public offering completed in July 2026.
• Secured exclusive world-wide rights to NXP900 through an agreement with the University of Edinburgh in Scotland.

What Sets Nuvectis Apart?

Nuvectis focuses on precision medicines that target specific biological pathways to bypass traditional drug resistance in cancer cells. Its portfolio includes a Factor B inhibitor designed for once-daily dosing, which may offer more convenience than existing twice-daily treatments.

A Look at the Numbers

• Net loss was $13.1 million for the six-month period ended June 30, 2026, compared to $11.7 million in the same period in 2025.
• Research and development expenses were $8.8 million in the first half of 2026, an increase of $1.5 million compared to the same period in 2025.
• Cash and cash equivalents totaled $22.2 million as of June 30, 2026, prior to the completion of a July 2026 public offering.
• General and administrative expenses decreased to $4.7 million for the six-month period ended June 30, 2026.

The Road Ahead

Nuvectis has transitioned from an early-stage startup to a clinical-stage firm with a diverse pipeline of licensed precision therapies. The company continues to focus on advancing its drug candidates through complex regulatory and clinical milestones.